These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36113265)

  • 1. Lactate dehydrogenase A inhibitors with a 2,8-dioxabicyclo[3.3.1]nonane scaffold: A contribution to molecular therapies for primary hyperoxalurias.
    Alejo-Armijo A; Cuadrado C; Altarejos J; Fernandes MX; Salido E; Diaz-Gavilan M; Salido S
    Bioorg Chem; 2022 Dec; 129():106127. PubMed ID: 36113265
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and
    Salido S; Alejo-Armijo A; Altarejos J
    Int J Mol Sci; 2023 Jun; 24(12):. PubMed ID: 37373073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Chitosan derivatives as nanocarriers for hLDHA inhibitors delivery to hepatic cells: A selective strategy for targeting primary hyperoxaluria diseases.
    Salido S; Alejo-Armijo A; Parola AJ; Sebastián V; Alejo T; Irusta S; Arruebo M; Altarejos J
    Int J Pharm; 2022 Nov; 627():122224. PubMed ID: 36181922
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Specific Inhibition of Hepatic Lactate Dehydrogenase Reduces Oxalate Production in Mouse Models of Primary Hyperoxaluria.
    Lai C; Pursell N; Gierut J; Saxena U; Zhou W; Dills M; Diwanji R; Dutta C; Koser M; Nazef N; Storr R; Kim B; Martin-Higueras C; Salido E; Wang W; Abrams M; Dudek H; Brown BD
    Mol Ther; 2018 Aug; 26(8):1983-1995. PubMed ID: 29914758
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effects of the inactivation of Hydroxyproline dehydrogenase on urinary oxalate and glycolate excretion in mouse models of primary hyperoxaluria.
    Buchalski B; Wood KD; Challa A; Fargue S; Holmes RP; Lowther WT; Knight J
    Biochim Biophys Acta Mol Basis Dis; 2020 Mar; 1866(3):165633. PubMed ID: 31821850
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduction in urinary oxalate excretion in mouse models of Primary Hyperoxaluria by RNA interference inhibition of liver lactate dehydrogenase activity.
    Wood KD; Holmes RP; Erbe D; Liebow A; Fargue S; Knight J
    Biochim Biophys Acta Mol Basis Dis; 2019 Sep; 1865(9):2203-2209. PubMed ID: 31055082
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New salicylic acid derivatives, double inhibitors of glycolate oxidase and lactate dehydrogenase, as effective agents decreasing oxalate production.
    Moya-Garzon MD; Rodriguez-Rodriguez B; Martin-Higueras C; Franco-Montalban F; Fernandes MX; Gomez-Vidal JA; Pey AL; Salido E; Diaz-Gavilan M
    Eur J Med Chem; 2022 Jul; 237():114396. PubMed ID: 35500475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. New therapeutics for primary hyperoxaluria type 1.
    Dejban P; Lieske JC
    Curr Opin Nephrol Hypertens; 2022 Jul; 31(4):344-350. PubMed ID: 35266883
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Salicylic Acid Derivatives Inhibit Oxalate Production in Mouse Hepatocytes with Primary Hyperoxaluria Type 1.
    Moya-Garzón MD; Martín Higueras C; Peñalver P; Romera M; Fernandes MX; Franco-Montalbán F; Gómez-Vidal JA; Salido E; Díaz-Gavilán M
    J Med Chem; 2018 Aug; 61(16):7144-7167. PubMed ID: 30028141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hydroxyproline Metabolism and Oxalate Synthesis in Primary Hyperoxaluria.
    Fargue S; Milliner DS; Knight J; Olson JB; Lowther WT; Holmes RP
    J Am Soc Nephrol; 2018 Jun; 29(6):1615-1623. PubMed ID: 29588429
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of alanine supplementation on oxalate synthesis.
    Wood KD; Freeman BL; Killian ME; Lai WS; Assimos D; Knight J; Fargue S
    Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165981. PubMed ID: 33002578
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Nine novel HOGA1 gene mutations identified in primary hyperoxaluria type 3 and distinct clinical and biochemical characteristics in Chinese children.
    Fang X; He L; Xu G; Lin H; Xu M; Geng H
    Pediatr Nephrol; 2019 Oct; 34(10):1785-1790. PubMed ID: 31123811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The retinal phenotype in primary hyperoxaluria type 2 and 3.
    Birtel J; Diederen RM; Herrmann P; Kaspar S; Beck BB; Garrelfs SF; Hoppe B; Charbel Issa P
    Pediatr Nephrol; 2023 May; 38(5):1485-1490. PubMed ID: 36260161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of stiripentol on urine oxalate excretion].
    Letavernier E; Daudon M
    Nephrol Ther; 2021 Apr; 17S():S95-S99. PubMed ID: 33910706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary hyperoxaluria type 1: novel therapies at a glance.
    Bacchetta J; Lieske JC
    Clin Kidney J; 2022 May; 15(Suppl 1):i17-i22. PubMed ID: 35592618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multiplex gene editing reduces oxalate production in primary hyperoxaluria type 1.
    Zheng R; Zhang DX; Shao YJ; Fang XL; Yang L; Huo YN; Li DL; Geng HQ
    Zool Res; 2023 Nov; 44(6):993-1002. PubMed ID: 37759334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Stiripentol identifies a therapeutic target to reduce oxaluria.
    Letavernier E; Daudon M
    Curr Opin Nephrol Hypertens; 2020 Jul; 29(4):394-399. PubMed ID: 32452916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Primary hyperoxaluria type III--a model for studying perturbations in glyoxylate metabolism.
    Belostotsky R; Pitt JJ; Frishberg Y
    J Mol Med (Berl); 2012 Dec; 90(12):1497-504. PubMed ID: 22729392
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stiripentol protects against calcium oxalate nephrolithiasis and ethylene glycol poisoning.
    Le Dudal M; Huguet L; Perez J; Vandermeersch S; Bouderlique E; Tang E; Martori C; Chemaly N; Nabbout R; Haymann JP; Frochot V; Baud L; Deschênes G; Daudon M; Letavernier E
    J Clin Invest; 2019 Apr; 129(6):2571-2577. PubMed ID: 30946030
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Metabolism of (13)C5-hydroxyproline in mouse models of Primary Hyperoxaluria and its inhibition by RNAi therapeutics targeting liver glycolate oxidase and hydroxyproline dehydrogenase.
    Li X; Knight J; Fargue S; Buchalski B; Guan Z; Inscho EW; Liebow A; Fitzgerald K; Querbes W; Todd Lowther W; Holmes RP
    Biochim Biophys Acta; 2016 Feb; 1862(2):233-9. PubMed ID: 26655602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.